{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:03:49Z","timestamp":1779329029061,"version":"3.51.4"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T00:00:00Z","timestamp":1394755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) plays an essential role in the degradation of low\u2010density lipoprotein C (LDL\u2010C) receptors, and PCSK9 inhibitors have recently emerged as a potential treatment option to reduce LDL\u2010C. Our paper reviewed the current available Phase II clinical trials of <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9 inhibitors for the treatment of dyslipidemia. A second objective of this review was to evaluate the potential clinical role of <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9 inhibitors in the management of dyslipidemia. Studies evaluating the efficacy and safety of any <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>9 inhibitors in patients with dyslipidemia were included. The monoclonal antibodies <jats:styled-content style=\"fixed-case\">REGN<\/jats:styled-content>727\/<jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content>236553 and <jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content>145 have the most published clinical data. Seven phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trials were retrieved that evaluated the efficacy and safety of <jats:styled-content style=\"fixed-case\">REGN<\/jats:styled-content>727\/<jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content>236553 or <jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content>145 in patients with either hypercholesterolemia or heterozygous familial hypercholesterolemia (He<jats:styled-content style=\"fixed-case\">FH<\/jats:styled-content>). These two agents significantly decreased <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C levels either as monotherapy or in combination with other lipid\u2010lowering agents. <jats:styled-content style=\"fixed-case\">REGN<\/jats:styled-content>727\/<jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content>236553 and <jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content>145 have been well tolerated. The ongoing phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> trials of these two agents are summarized. <jats:styled-content style=\"fixed-case\">REGN<\/jats:styled-content>727\/<jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content>236553 and <jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content>145 have demonstrated the potential to further decrease <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C levels when added to conventional lipid\u2010lowering therapy. Morbidity and mortality data are required to define their roles in clinical practice.<\/jats:p>","DOI":"10.1111\/1755-5922.12056","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T12:42:51Z","timestamp":1387456971000},"page":"82-88","source":"Crossref","is-referenced-by-count":13,"title":["An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low\u2010Density Lipoprotein Cholesterol"],"prefix":"10.1111","volume":"32","author":[{"given":"Hua","family":"Ling","sequence":"first","affiliation":[{"name":"The Cardiac Center of Creighton University Omaha NE USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy L.","family":"Burns","sequence":"additional","affiliation":[{"name":"The Cardiac Center of Creighton University Omaha NE USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Hilleman","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Health Professions  Creighton University Omaha NE USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402133101"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410077200"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2006.12.008"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.091280"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R026658"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1509"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-012-0345-z"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105803"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.03.039"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(12)61380-1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.007"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201832"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.25790"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61771-1"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61770-X"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2003.11.010"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.2008.00436.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.09.014"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.03.027"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60771-5"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.144055"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22911"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-005-5686-z"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-008-9364-3"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.10.002"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M300203-JLR200"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000134621.14315.43"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2011.172932"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700437-JLR200"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M008144"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.05.027"},{"key":"e_1_2_8_39_1","unstructured":"Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercho\u2010lesterolemia 2012[cited 2013 1\/11]. Available from:http:\/\/investor.regeneron.com\/releasedetail.cfm?ReleaseID=718525."},{"key":"e_1_2_8_40_1","unstructured":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). Available from:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764633?term=FOURIER&rank=1."}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12056","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:49:20Z","timestamp":1696276160000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,14]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/1755-5922.12056"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12056","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,14]]}}}